General
Preferred name
PAC-14028
Synonyms
asivatrep ()
P&D ID
PD058063
CAS
1005168-10-4
Tags
available
drug candidate
Drug indication
Atopic dermatitis
Drug Status
investigational
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION PAC-14028 is an antagonist of the transient receptor potential vanilloid type 1 (TRPV1) channel, developed by AmorePacific for anti-inflammatory potential in refractory dermatoses . It is claimed as example 230 in patent US7858621 . PAC-14028 is administered topically for skin inflammation. The formal IUPAC name for this compound matches that submitted to the WHO for proposed INN asivatrep.
DESCRIPTION Asivatrep (PAC-14028) is an antagonist of the transient receptor potential vanilloid type 1 (TRPV1) channel, developed by AmorePacific for anti-inflammatory potential in refractory dermatoses . It is claimed as example 230 in patent US7858621 . PAC-14028 is administered topically for skin inflammation. (GtoPdb)
Compound Sets
6
Drug Repurposing Hub
DrugBank
DB12428
DrugMAP
DM3816P
Guide to Pharmacology
9621
MedChem Express Bioactive Compound Library
HY-12777
ReFrame library
External IDs
14
Properties
(calculated by RDKit )
Molecular Weight
491.13
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
8
Ring Count
2
Aromatic Ring Count
2
cLogP
4.59
TPSA
88.16
Fraction CSP3
0.33
Chiral centers
1.0
Largest ring
6.0
QED
0.42
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
MOA
transient receptor potential channel antagonist
Pathway
Membrane Transporter/Ion Channel
Neuronal Signaling
Target
TRP Channel
Source data